Dr. Adnane Sellam joined Laval University in August 2013 as an assistant professor at the School of Medicine (Department of Microbiology-Infectious Disease and Immunology) and new member of the CHU de Québec research center and its vibrant community of researchers. As a principal investigator, Dr Sellam is affiliated to the Centre de Recherche en Infectiologie (CRI-CHUL) and the centre de recherche en données massives de l’Université Laval (CRDM-UL). Dr Sellam held a Ph.D. from University of Angers (France) and undertook two productive postdoctoral trainings at Université de Montréal and University McGill/NRC Canada. Dr. Sellam is an expert on Systems biology and genomics, applied to fungal pathogens. His research has been funded by different recognized provincial (CQDM, FRQS, CHUQ foundation, Merck-U Laval) and federal (NSERC, CFI) funding organisms.
Candida albicans is an opportunistic pathogen responsible for various non-life-threatening infections, such as oral thrush and vaginitis. This pathogen is also a major cause of morbidity and mortality in bloodstream infections, especially in immunosuppressed individuals. The arsenal of clinically active antifungal compounds is limited, because of the eukaryotic nature of this yeast, which makes it like its human host. In addition, many cases of clinical resistance to all anti-Candida drugs have been reported. Currently, the pipeline of pharmaceutical companies for new drugs targeting C. albicans infections is completely dry. Thus, discovery of new drugs is of utmost urgency to fight C. albicans infections. The purpose of Dr. Sellam’s research is to gain a deep knowledge on mechanisms that control the virulence of C. albicans. This will lead to identification of proteins or biological processes that are required for the establishment of the infection. Screens of chemical libraries will identify bioactive molecules that inhibit these proteins, and consequently limit the infections.
The main objective of my research program is to decipher C. albicans regulatory circuits that control adaptation to hypoxia and cell size homeostasis. These biological processes are both intimately linked to C. albicans virulence. Dr. Sellam’s team is also screening different chemical libraries to find small molecules inhibiting filamentation and biofilm formation, which are key manifestations of C. albicans pathogenicity.
2705, boulevard Laurier
Canada G1V 4G2
The Genomic Landscape of the Fungus-Specific SWI/SNF Complex Subunit, Snf6, in Candida albicans.Journal Article
mSphere, 2 (6), 2017, ISSN: 2379-5042.
The Human Gut Microbial Metabolome Modulates Fungal Growth via the TOR Signaling Pathway.Journal Article
mSphere, 2 (6), 2017, ISSN: 2379-5042.
Genome-Wide Screen for Haploinsufficient Cell Size Genes in the Opportunistic Yeast Candida albicans.Journal Article
G3 (Bethesda), 7 (2), pp. 355-360, 2017, ISSN: 2160-1836.
The BioGRID interaction database: 2017 update.Journal Article
Nucleic Acids Res, 45 (D1), pp. D369-D379, 2017, ISSN: 0305-1048.
pH-Dependant Antifungal Activity of Valproic Acid against the Human Fungal Pathogen Candida albicans.Journal Article
Front Microbiol, 8 , pp. 1956, 2017, ISSN: 1664-302X.
Valproate inhibits MAP kinase signalling and cell cycle progression in S. cerevisiae.Journal Article
Sci Rep, 6 , pp. 36013, 2016, ISSN: 2045-2322.
Chromosome-wide histone deacetylation by sirtuins prevents hyperactivation of DNA damage-induced signaling upon replicative stress.Journal Article
Nucleic Acids Res, 44 (6), pp. 2706-26, 2016, ISSN: 0305-1048.
BioGRID: A Resource for Studying Biological Interactions in Yeast.Journal Article
Cold Spring Harb Protoc, 2016 (1), pp. pdb.top080754, 2016, ISSN: 1559-6095.
Use of the BioGRID Database for Analysis of Yeast Protein and Genetic Interactions.Journal Article
Cold Spring Harb Protoc, 2016 (1), pp. pdb.prot088880, 2016, ISSN: 1559-6095.
Use of phylogenetical analysis to predict susceptibility of pathogenic Candida spp. to antifungal drugs.Journal Article
J Microbiol Methods, 131 , pp. 51-60, 2016, ISSN: 0167-7012.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche en données massives, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 2016-06-07 to 2021-06-06
- Découverte de thérapies antifongiques et étude du pouvoir pathogène des champignons du genre Candida, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30
- The transcriptional circuitry controlling the metabolic flexibility and host colonization under hypoxia in the human fungal pathogen Candida albicans, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2022-03-31
Recently finished projects
- Étude du déterminisme du pouvoir pathogène de la levure pathogène Candida albicans par des approches de génomiques et de biologie des systèmes., Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2015-07-01 to 2019-06-30
- Repurposing valproic acid, a widely prescribed anticonvulsant, to fight vulvovaginal candidiasis, Subvention, Fondation de l'Université Laval, from 2016-09-15 to 2019-10-31
- Systems biology of the hypoxic adaptation., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2014-04-01 to 2020-03-31